A process for producing a surfactant having two head groups and a single tail group per molecule, including steps of: producing a compound of Formula (1) from ethanol and carbon disulfide; producing a compound of Formula (2) from a carboxylic acid and bromine; producing a compound of Formula (3) from the compound of Formula (2) and methanol; producing a compound of Formula (4) from the compound of Formula (1) and the compound of Formula (3); and producing a compound of Formula (5) from the compound of Formula (4) by a direct oxidation process or by a peracid oxidation process. The surfactant produced by the process has lower critical micelle concentration and enables a lower surface tension of a liquid as compared with prior surfactants with two head groups per molecule, thereby enabling the amount of surfactant required and thus the cost to be substantially reduced.

A process for producing a surfactant having two head groups and a single tail group per molecule, including steps of: producing a compound of Formula (1) from ethanol and carbon disulfide; producing a compound of Formula (2) from a carboxylic acid and bromine; producing a compound of Formula (3) from the compound of Formula (2) and methanol; producing a compound of Formula (4) from the compound of Formula (1) and the compound of Formula (3); and producing a compound of Formula (5) from the compound of Formula (4) by a direct oxidation process or by a peracid oxidation process. The surfactant produced by the process has lower critical micelle concentration and enables a lower surface tension of a liquid as compared with prior surfactants with two head groups per molecule, thereby enabling the amount of surfactant required and thus the cost to be substantially reduced.

The present invention relates to an improved and economical process for enantioselective synthesis and purification of a novel key intermediate of Brivaracetam. Further, the present invention also relates to a process for the preparation of a chirally pure Brivaracetam of formula I utilizing the said intermediate.

##STR00001##

The present invention relates to an improved and economical process for enantioselective synthesis and purification of a novel key intermediate of Brivaracetam. Further, the present invention also relates to a process for the preparation of a chirally pure Brivaracetam of formula I utilizing the said intermediate.

##STR00001##

The present invention's purpose is to provide: a molecular-weight controlling agent for radical polymerization which enables controlled radical polymerization of a water-soluble monomer in an aqueous medium; a method for producing a polymer of a water-soluble vinyl monomer using the same; and a water-soluble vinyl monomer polymer. The present invention provides a molecular-weight controlling agent for radical polymerization characterized in that the agent comprises, as its active ingredient, an iodine compound represented by formula (1) and in that the solubility of the active ingredient in water is 0.5 weight % or more at 20 C.

##STR00001##

In the formula, R.sup.1 is COOX, CONR.sup.4R.sup.5, an aromatic group or a cyano group, X is a hydrogen atom, an aliphatic group, an alkali metal, an alkaline earth metal, an organic ammonium or an ammonium, and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each independently a hydrogen atom, an aromatic group or an aliphatic group.

The present invention's purpose is to provide: a molecular-weight controlling agent for radical polymerization which enables controlled radical polymerization of a water-soluble monomer in an aqueous medium; a method for producing a polymer of a water-soluble vinyl monomer using the same; and a water-soluble vinyl monomer polymer. The present invention provides a molecular-weight controlling agent for radical polymerization characterized in that the agent comprises, as its active ingredient, an iodine compound represented by formula (1) and in that the solubility of the active ingredient in water is 0.5 weight % or more at 20 C.

##STR00001##

In the formula, R.sup.1 is COOX, CONR.sup.4R.sup.5, an aromatic group or a cyano group, X is a hydrogen atom, an aliphatic group, an alkali metal, an alkaline earth metal, an organic ammonium or an ammonium, and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each independently a hydrogen atom, an aromatic group or an aliphatic group.

A process for synthesizing a product of formula Br(CH.sub.2).sub.nR by hydrobromination, by reacting: a reagent of formula (I) R1-CHCHR2 in which R1 and R2, identical or different, are chosen from H or an alkyl radical comprising 1 to 30 carbon atoms, which is saturated or unsaturated, linear or branched, functionalized or non-functionalized, with a molar excess of HBr relative to the reagent of formula (I), in the presence of a radical initiator, and optionally in the presence of at least one solvent, said process including a step A of mixing at least reagent I and the HBr, each of the latter arriving in the form of a flow of liquid into a mixing device dA.

A process for synthesizing a product of formula Br(CH.sub.2).sub.nR by hydrobromination, by reacting: a reagent of formula (I) R1-CHCHR2 in which R1 and R2, identical or different, are chosen from H or an alkyl radical comprising 1 to 30 carbon atoms, which is saturated or unsaturated, linear or branched, functionalized or non-functionalized, with a molar excess of HBr relative to the reagent of formula (I), in the presence of a radical initiator, and optionally in the presence of at least one solvent, said process including a step A of mixing at least reagent I and the HBr, each of the latter arriving in the form of a flow of liquid into a mixing device dA.

The present disclosure is directed to a novel class of peptide-like oligomers called peptide tertiary amides (PTAs) and a combinatorial library of PTAs along with synthetic routes for the preparation of large combinatorial libraries of these compounds. The peptide tertiary amides provide an exceptional source of high affinity and selective protein ligands that are useful as tools for biological research and as drug leads, among others.

The present disclosure is directed to a novel class of peptide-like oligomers called peptide tertiary amides (PTAs) and a combinatorial library of PTAs along with synthetic routes for the preparation of large combinatorial libraries of these compounds. The peptide tertiary amides provide an exceptional source of high affinity and selective protein ligands that are useful as tools for biological research and as drug leads, among others.